View in EDS HTML Full Text

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.

Saved in:
Bibliographic Details
Title: Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
Authors: Ludwig H; First Department of Medicine, Wilhelminen Cancer Research Institute, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria. Electronic address: heinz.ludwig@extern.gesundheitsverbund.at., Ramasamy K; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Mateos MV; Department of Hematology, University Hospital of Salamanca, IBSAL, CIC, IBMCC (USAL-CSIC), Salamanca, Spain., Kishore B; Heart of England/University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Gergely V; Faculty of Medicine Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary., Ladicka M; National Cancer Institute, Bratislava, Slovakia., Ori A; MediNeos, Observational Research, Modena, Italy., Simoni L; MediNeos, Observational Research, Modena, Italy., Bent-Ennakhil N; Takeda Pharmaceuticals International AG, Zurich, Switzerland., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA., Gavini F; Takeda Pharmaceuticals International AG, Zurich, Switzerland., Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Hájek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Feb; Vol. 24 (2), pp. e40-e49.e3. Date of Electronic Publication: 2023 Oct 14.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37996265
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ludwig+H%22">Ludwig H</searchLink>; First Department of Medicine, Wilhelminen Cancer Research Institute, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria. Electronic address: heinz.ludwig@extern.gesundheitsverbund.at.<br /><searchLink fieldCode="AU" term="%22Ramasamy+K%22">Ramasamy K</searchLink>; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; Department of Hematology, University Hospital of Salamanca, IBSAL, CIC, IBMCC (USAL-CSIC), Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Kishore+B%22">Kishore B</searchLink>; Heart of England/University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gergely+V%22">Gergely V</searchLink>; Faculty of Medicine Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Ladicka+M%22">Ladicka M</searchLink>; National Cancer Institute, Bratislava, Slovakia.<br /><searchLink fieldCode="AU" term="%22Ori+A%22">Ori A</searchLink>; MediNeos, Observational Research, Modena, Italy.<br /><searchLink fieldCode="AU" term="%22Simoni+L%22">Simoni L</searchLink>; MediNeos, Observational Research, Modena, Italy.<br /><searchLink fieldCode="AU" term="%22Bent-Ennakhil+N%22">Bent-Ennakhil N</searchLink>; Takeda Pharmaceuticals International AG, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Stull+DM%22">Stull DM</searchLink>; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA.<br /><searchLink fieldCode="AU" term="%22Gavini+F%22">Gavini F</searchLink>; Takeda Pharmaceuticals International AG, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Terpos+E%22">Terpos E</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Hájek+R%22">Hájek R</searchLink>; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101525386%22">Clinical lymphoma, myeloma & leukemia</searchLink> [Clin Lymphoma Myeloma Leuk] 2024 Feb; Vol. 24 (2), pp. e40-e49.e3. <i>Date of Electronic Publication: </i>2023 Oct 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101525386 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2152-2669 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221522669%22">21522669 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lymphoma Myeloma Leuk <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37996265
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.clml.2023.10.003
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e40
    Titles:
      – TitleFull: Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ludwig H
      – PersonEntity:
          Name:
            NameFull: Ramasamy K
      – PersonEntity:
          Name:
            NameFull: Mateos MV
      – PersonEntity:
          Name:
            NameFull: Kishore B
      – PersonEntity:
          Name:
            NameFull: Gergely V
      – PersonEntity:
          Name:
            NameFull: Ladicka M
      – PersonEntity:
          Name:
            NameFull: Ori A
      – PersonEntity:
          Name:
            NameFull: Simoni L
      – PersonEntity:
          Name:
            NameFull: Bent-Ennakhil N
      – PersonEntity:
          Name:
            NameFull: Stull DM
      – PersonEntity:
          Name:
            NameFull: Gavini F
      – PersonEntity:
          Name:
            NameFull: Terpos E
      – PersonEntity:
          Name:
            NameFull: Hájek R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2024 Feb
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2152-2669
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Clinical lymphoma, myeloma & leukemia
              Type: main
ResultId 1